ARCHIVES

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

This article is from The Cancer Letter archive.

Vol. 29 No. 41 | November 7, 2003

Download PDF Visit The Full Archive

Related Articles

O’Shaughnessy, Burris To Present for Genentech At FDA Hearing At June 28-29

June 10, 2011

Duke Halts Third Trial; Coauthor Disputes Claim That Data Validation Was Blinded

October 23, 2009

Senate Authorizes $30 Million For Childhood Cancer Clinical Trials Research.

July 18, 2008

Neutron Clinical Trials Contract Concept Approved

June 22, 1984

Science Policy: Second-Hand Smoke Linked To Lung Cancer, Other Health Effects

November 26, 1999

Diane Fink Accepts VP Job With ACS

April 3, 1981